

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5137310

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH	06/22/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MEMORIAL SLOAN KETTERING CANCER CENTER
<b>Street Address:</b>	1275 YORK AVENUE
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10065
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7488718
Patent Number:	8765687
Patent Number:	9233149
Patent Number:	7598221
Patent Number:	9265816
Application Number:	14995955
PCT Number:	US2004040347
PCT Number:	US2006040719
PCT Number:	US2007008853
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(646)878-0801
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	646-878-0800
<b>Email:</b>	USPTO@pearlcohen.com
<b>Correspondent Name:</b>	PEARL COHEN ZEDEK LATZER BARATZ LLP
<b>Address Line 1:</b>	1500 BROADWAY
<b>Address Line 2:</b>	12TH FLOOR
<b>Address Line 4:</b>	NEW YORK, NEW YORK 10036
<b>ATTORNEY DOCKET NUMBER:</b>	701445-38-00
<b>NAME OF SUBMITTER:</b>	LEAH HERSZBERG

PATENT

<b>SIGNATURE:</b>	/LHZ/
<b>DATE SIGNED:</b>	09/12/2018
<b>Total Attachments: 7</b> source=701445-38-03-EXECUTED-ASSGNM-22JUN18#page1.tif source=701445-38-03-EXECUTED-ASSGNM-22JUN18#page2.tif source=701445-38-03-EXECUTED-ASSGNM-22JUN18#page3.tif source=701445-38-03-EXECUTED-ASSGNM-22JUN18#page4.tif source=701445-38-03-EXECUTED-ASSGNM-22JUN18#page5.tif source=701445-38-03-EXECUTED-ASSGNM-22JUN18#page6.tif source=701445-38-03-EXECUTED-ASSGNM-22JUN18#page7.tif	

## CONFIRMATORY ASSIGNMENT

In consideration of One Dollar (\$1.00), and other good and valuable consideration, the Receipt of which is hereby acknowledged, we the undersigned, **Sloan Kettering Institute for Cancer Research**, having a business address at 1275 York Avenue, New York, NY 10065, and to the extent that **Memorial Hospital for Cancer and Allied Diseases**, having a business address at 1275 York Avenue, New York, NY 10065, has any rights therein, hereby confirm that they have sold, have assigned and have transferred to:

**Memorial Sloan Kettering Cancer Center**, located at 1275 York Avenue, New York, NY 10065, its successors, assigns and legal representatives (hereinafter, the "Assignee"), the entire right, title and interest for all countries, in and to any and all inventions which are disclosed and claimed, and any and all inventions which are disclosed but not claimed in the applications and patents listed below:

Title	Application Serial No.	Patent/Publication No.	Docket Nos.
SYNTHETIC HLA BINDING PEPTIDE ANALOGUES AND USES THEREOF	International patent application no. PCT/US2004/040347	Publication no. WO2005053618	SK1074-03 P-7661-PC SEL.MSKC107403WO
	European Patent Application no. 04812790.6	European patent no. 1708732. Validated in Switzerland/ Liechtenstein, Germany, Spain, France, Great Britain and Italy	SK1074-02 P-7661-EP SEL.MSKC107402EP
	US patent application no. 10/999,425 (an assignment was recorded at the USPTO on March 2, 2005, at Reel 015717, Frame 0345)	US patent no. 7,488,718	SK1074-06 P-7661-US SEL.MSKC107406
	Australian patent application no. 2004294354	Australian patent no. 2004294354	SK1074-05 P-7661-AU SEL.MSKC107405AU
	Canadian patent application no. 2548235	Canadian patent no. 2548135	SK1074-04 P-7661-CA SEL.MSKC107404CA
WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME	International application no. PCT/US2006/040719	Publication no. WO2007047764	SK1219-03 P-8273-PC SEL.MSKC121903WO
	European patent application No. 06826190.8	European patent no. 1951281. Validated in Switzerland/ Liechtenstein, Germany,	SK1219-04 P-8273-EP SEL.MSKC121904EP

Title	Application Serial No.	Patent/Publication No.	Docket Nos.
		Ireland, Spain, France, Great Britain and Italy	
	European patent application No. 12172030.4	European patent no. 2565201. Validated in Switzerland/ Liechtenstein, Germany, Ireland, Spain, France, Great Britain and Italy	SK1219-09 P-8273-EP1 SEL.MSKC121909EP
	Australian patent application no. 2006304573	Australian patent no. 2006304573	SK1219-08 P-8273-AU SEL.MSKC121908AU
	Canadian patent application no. 2626238	Canadian patent no. 2626238	SK1219-07 P-8273-CA SEL.MSKC121907CA
	Canadian patent application no. 2900087	Pending	SK1219-18 P-8273-CA1 SEL.MSKC121918CA
	US patent application no. 12/083,731 (an assignment was recorded at the USPTO on January 28, 2006, at Reel 037612, Frame 0573)	US patent no. 8,765,687 Assignment recorded:	SK1219-06 P-8273-US SEL.MSKC121906
	US patent application no. 028,329 (an assignment was recorded at the USPTO on August 26, 2014, at Reel 033613, Frame 0551)	US patent no. 9,233,149	SK1219-10 P-8273-US1 SEL.MSKC127610
SYNTHETIC HLA BINDING PEPTIDE ANALOGUES AND USES THEREOF	US patent application no. 11/223139 (an assignment was recorded at the USPTO on December 15, 2005, at Reel 016898, Frame 0016)	US patent no. 7,598,221	SK1225-01 P-8269-US SEL.MSKC122501
IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF	International patent application no. PCT/US2007/008853	Publication no. WO2007120673	SK1233-03 P-8625-PC SEL.MSKC123303WO
	European patent application No. 07755205.7	European patent no. 2010209. Validated in Austria, Belgium, Switzerland/ Liechtenstein, Germany, Spain, Finland, France, Great Britain, Greece, Ireland, Italy,	SK1233-05 P-8625-EP SEL.MSKC123305EP

Title	Application Serial No.	Patent/Publication No.	Docket Nos.
		Netherlands, Poland, Romania and Turkey	
	US patent application no. 12/296,777 (an assignment was recorded at the USPTO on January 28, 2016, at Reel 37611, Frame 0980)	US patent no. 9,265,816	SK1233-04 P-8625-US SEL.MSKC123304
	US patent application no. 14/995,955 (an assignment was recorded at the USPTO on March 15, 2017, at Reel 41575, Frame 0802)	Pending. US patent application publication no. US-2016-0368948-A1	SK1233-07 P-8625-US1 SEL.MSKC123307
	Canadian patent application no. 2634766	Pending	SK1233-06 P-8625-CA SEL.MSKC123306CA

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other applications for U.S. Letters Patent or other related property rights in any and all foreign countries which have been or shall be filed on any of said inventions disclosed in said application; and in and to all original and reissued patents or related foreign documents which have been or shall be issued on said inventions; and including the Assignor's right in and to all revenue, income, royalties, damages and payments now or hereafter due or payable with respect to any Letters Patent which may be granted, and in and to all causes of action (either in law or in equity), and the right to sue, counterclaim, and recover for past, present and future infringement of the rights assigned or to be assigned under this Assignment;

Authorize and request the Commissioner of Patents of the United States to issue to said Assignee, the corporation above named, its successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said inventions or any of them disclosed in said application;

Agree that said Assignee may apply for and receive foreign Letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign Letters Patent or other rights, the priority of the aforesaid United States patent application under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention or under any other available international agreement; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the under-signed or the

undersigned's executors or administrators will, for the United States and all foreign countries, execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications or other documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and representatives, all facts known and documents available to the undersigned relating to said inventions and the history thereof; testify in all legal proceedings; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said Assignee, its successors, assigns and legal representatives; and

**COVENANT** with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

ASSIGNOR: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

By:

Eric Cottington

Name: Eric Cottington, Ph.D.

Title: Senior Vice President  
Research and Technology Management  
Sloan Kettering Institute for Cancer Research


Date: 6-22-18  
[day / month / year]

STATE OF New York :

COUNTY OF New York :

This 22<sup>nd</sup> day of June, 2018, before me personally came the  
above-named Eric Cottington, Ph.D., to me personally known as the individual who executed  
the same of his/her own free will for the purposes therein set forth.

Jill A. Fraser  
Notary Public



Commission expires on 12/9/2021.

ASSIGNOR: MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES

By: \_\_\_\_\_

*[Signature]*

Name: Eric Cottingham, Ph.D.

Title: Senior Vice President

Research and Technology Management

Memorial Hospital for Cancer and Allied Diseases

Date: \_\_\_\_\_

6 - 22 - 18


[day / month / year]

STATE OF NEW YORK:

COUNTY OF NEW YORK:

This 22<sup>nd</sup> day of June, 2018, before me personally came the  
above-named Eric Cottingham, PhD, to me personally known as the individual who executed  
the same of his/her own free will for the purposes therein set forth.

*[Signature]*  
\_\_\_\_\_  
Notary Public



Commission expires on 12/9/2021.



ASSIGNEE: MEMORIAL SLOAN-KETTERING CANCER CENTER

By:

Eric Cottington

Name: Eric Cottington, Ph.D.

Title: Senior Vice President  
Research and Technology Management  
Memorial Hospital for Cancer and Allied Diseases


Date: 6-22-18  
[day / month / year]

STATE OF NEW YORK:

COUNTY OF NEW YORK:

This 22nd day of June, 2018, before me personally came the  
above-named Eric Cottington, PhD, to me personally known as the individual who executed  
the same of his/her own free will for the purposes therein set forth.

Jill A Fraser  
Notary Public



Commission expires on 12/9/2021.